Ocugen (OCGN) Competitors $1.00 +0.04 (+4.35%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.02 +0.02 (+2.50%) As of 08:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN vs. MRNA, PFE, AUPH, CALT, PAHC, PRAX, MENS, SANA, DYN, and AMPHShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include Moderna (MRNA), Pfizer (PFE), Aurinia Pharmaceuticals (AUPH), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Praxis Precision Medicines (PRAX), Jyong Biotech (MENS), Sana Biotechnology (SANA), Dyne Therapeutics (DYN), and Amphastar Pharmaceuticals (AMPH). Ocugen vs. Its Competitors Moderna Pfizer Aurinia Pharmaceuticals Calliditas Therapeutics AB (publ) Phibro Animal Health Praxis Precision Medicines Jyong Biotech Sana Biotechnology Dyne Therapeutics Amphastar Pharmaceuticals Moderna (NASDAQ:MRNA) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Do insiders and institutionals believe in MRNA or OCGN? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 11.0% of Moderna shares are owned by company insiders. Comparatively, 4.4% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, MRNA or OCGN? Moderna has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.84, indicating that its stock price is 284% more volatile than the S&P 500. Which has preferable earnings & valuation, MRNA or OCGN? Ocugen has lower revenue, but higher earnings than Moderna. Ocugen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.20-$3.56B-$7.53-3.53Ocugen$4.05M72.17-$54.05M-$0.20-5.00 Is MRNA or OCGN more profitable? Moderna has a net margin of -94.31% compared to Ocugen's net margin of -1,197.71%. Moderna's return on equity of -25.96% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% Ocugen -1,197.71%-255.25%-86.79% Does the media favor MRNA or OCGN? In the previous week, Moderna had 32 more articles in the media than Ocugen. MarketBeat recorded 48 mentions for Moderna and 16 mentions for Ocugen. Ocugen's average media sentiment score of 0.65 beat Moderna's score of 0.11 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 15 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 12 Negative mention(s) 1 Very Negative mention(s) Neutral Ocugen 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MRNA or OCGN? Moderna currently has a consensus target price of $43.59, indicating a potential upside of 63.80%. Ocugen has a consensus target price of $6.00, indicating a potential upside of 500.00%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryModerna beats Ocugen on 9 of the 16 factors compared between the two stocks. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$280.12M$2.98B$5.48B$9.56BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-5.0017.9729.9325.14Price / Sales72.17179.55375.2276.13Price / CashN/A41.8335.9458.58Price / Book100.007.238.105.59Net Income-$54.05M-$54.43M$3.26B$265.48M7 Day Performance0.64%0.22%0.68%1.22%1 Month Performance-4.76%5.59%2.45%0.39%1 Year Performance-21.88%9.98%27.72%23.47% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.779 of 5 stars$1.00+4.4%$6.00+500.0%-15.3%$280.12M$4.05M-5.0080Earnings ReportAnalyst RevisionMRNAModerna4.3246 of 5 stars$33.91-0.7%$46.11+36.0%-67.4%$13.11B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst RevisionPFEPfizer4.9867 of 5 stars$24.33-1.9%$28.55+17.3%-15.9%$138.33B$63.63B17.6381,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionAUPHAurinia Pharmaceuticals2.1475 of 5 stars$8.89-0.4%$11.50+29.4%+114.8%$1.20B$247.30M31.75300Insider TradeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.0935 of 5 stars$28.92-0.9%$24.40-15.6%+60.8%$1.17B$1.19B37.081,940Positive NewsAnalyst RevisionPRAXPraxis Precision Medicines1.6654 of 5 stars$55.65-6.0%$94.11+69.1%-9.1%$1.13B$8.55M-5.19110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMENSJyong BiotechN/A$14.48+4.9%N/AN/A$1.10BN/A0.0031Gap DownSANASana Biotechnology3.3016 of 5 stars$4.88-1.4%$9.17+87.8%-37.1%$1.10BN/A-5.55380News CoverageUpcoming EarningsGap DownDYNDyne Therapeutics3.3786 of 5 stars$9.31-6.4%$40.63+336.4%-73.5%$1.06BN/A-2.59100Upcoming EarningsAnalyst ForecastAMPHAmphastar Pharmaceuticals4.306 of 5 stars$22.24-0.6%$32.33+45.4%-44.4%$1.05B$730.66M8.062,028News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Moderna Alternatives Pfizer Alternatives Aurinia Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives Phibro Animal Health Alternatives Praxis Precision Medicines Alternatives Jyong Biotech Alternatives Sana Biotechnology Alternatives Dyne Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCGN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCGN Stock Alerts